This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Ocera Therapeutics Inc.

Drug Names(s): TZP-102

Description: TZP-102 is an orally available ghrelin agonist. Ghrelin is a peptide hormone known to stimulate both gastrointestinal motility and growth hormone release. TZP-102 was designed to affect gastrointestinal motility, but not growth hormone release, in order to avoid potential endocrine side effects. It is being developed for mild to moderate gastroparesis.

TZP-102 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug